Skip to main content

Tokyo Education Event, March 2023

Transfusion Medicine Updates Education Program

Header for Zoom Events

Advance Registration is now closed. For those planning to attend in person, on-site registration will be available as room capacity allows.

Agenda

13:00 - 13:30 Badge Pickup at Registration Desk
13:30 - 13:40 Welcome & Introductions
Dana Devine, PhD
President, BEST Collaborative
13:40 - 14:10 


Warm Autoantibodies – Updates and Evidence
Meghan Delaney, DO, MPH

The presence of warm autoantibodies in a patient’s sample complicates the serological evaluation and can make finding compatible blood difficult.  In this lecture Dr. Delaney will review some of the important literature about how to approach warm autoantibodies in the blood bank, as well as a large study that investigated the risk of red blood cell alloimmunization in patients who have underlying warm autoantibodies.
14:10 - 14:40 Plasma Transfusion in Bleeding – Updates and Evidence
Nancy Dunbar, MD

This presentation will review the evolution in the practice of plasma transfusion in traumatically injured bleeding patients including the use of thawed plasma, potentially incompatible group A plasma, and ratio based as well as current practice and recommendations for other bleeding populations.
14:40 - 15:10  Platelet Transfusion – Updates and Evidence
Simon Stanworth, MA, FRCP (Paeds, UK), PhD, FRCPath
This presentation will discuss the use of platelets for transfusion. Dr. Stanworth will share the findings from recent clinical randomized trials. This will include a description of how these trials are identifying harm, for example, a recent study, the PlaNeT2 trial, showing that platelet transfusions increase mortality and major bleeding in neonates.
15:10 - 15:30 Break
15:30 - 16:00 Home Transfusion – Updates and Evidence
Richard Kaufman,MD

The Covid-19 pandemic has accelerated a shift toward providing medical services outside of hospitals. Many healthcare systems are exploring providing blood transfusions to patients in their own homes. This session will: (1) review the risks and benefits of home transfusion; (2) illustrate how home transfusion programs vary internationally; and (3) describe how ongoing BEST Collaborative studies aim to optimize transfusion at home.
16:00 - 16:30 Pre-Transfusion Compatibility Testing: What, Why, When & How Frequently
Alyssa Ziman, MD

Pre-transfusion compatibility tests are performed in order to help prevent hemolytic transfusion reactions caused by antibodies of the ABO blood group system or by antibodies to other blood group antigens.   Policies defining the timing and frequency of testing vary by institution and clinical setting.  This topic will review the history of current practices, prevalence of alloimmunization in different patient populations, and recent literature evaluating the risk of alloimmunization based on different testing strategies.
16:30 - 16:50 Prospective survey of hematopoietic cell infusion-related adverse events in Japan
Kazuhiko Ikeda, MD, PhD

Adverse events associated with blood transfusions have been extensively surveyed, whereas surveillance of cell infusion in hematopoietic stem cell transplantation has been less rigorous. This presentation focuses on features of such hematopoietic cell infusion-related adverse events, among stem cell sources, ages, and infused cryoprotectants, clarified by our prospective multicenter survey. 
16:50 - 17:05 Transfusion-Associated Hyperkalemia: Cases, Caution, and Countermeasures
Kenneth Nollet, MD, PhD

This presentation considers recent publications in the context of transfusion medicine practice in Japan, where universal irradiation of allogeneic cellular transfusion products began at Fukushima Medical University in 1989, and progressed to become national policy in 2009.  Universal irradiation, availability of K+ filters, and national systems for blood management and hemovigilance make Japan a venue for further research into TAH.
17:05 - 17:15 Closing Remarks
Tadashi Matsushita, MD
President, Japan Society of Transfusion Medicine and Cell Therapy